Detalles de la búsqueda
1.
A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer.
Lung Cancer
; 146: 12-18, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32502923
Resultados
1 -
1
de 1
1
Próxima >
>>